Remaining Compound. Upon Lilly's written request, Generex will return or immediately destroy (as designated by Lilly) any Compound remaining upon completion of the Product Development Program.
Appears in 2 contracts
Sources: Development and License Agreement (Generex Biotechnology Corp), Development and License Agreement (Generex Biotechnology Corp)